Femilis LNG IUS
Description: IUS releasing ~20mcg of levonorgestrel daily, expected to last for at least 5 years. In vitro study suggest constant rate of LNG release similar to the Mirena. Four products with the Femilis name have been developed. They are various sizes, contain different amounts of levonorgestrel, and have different durations of use.
Product Details
User: Female
Hormonal: Yes
Delivery Method: Intrauterine
Duration Type: Long-acting
Duration: 5 years
Dose: 20 mcg
Active Pharmaceutical Ingredient (API): - levonorgestrel
- levonorgestrel
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: Contrel Research, Belgium, APCOR R&M, Belgium
Project Phase: Limited Market Availability
Development Stage: Regulatory
Active Development: Yes
Additional Information
References: Wildemeersch D, et al. (2005) Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Contraception. 71(6):465-9.
Wildemeersch D, et al. (2016) Femilis 60 Levonorgestrel-Releasing Intrauterine System-A Review of 10 Years of Clinical Experience. Clin Med Insights Reprod Health. 10: 19-27.
Wildemeersch D, et al. (2017) Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS. Gynecol Endocrinol. 33(3):223-226.
Wildemeersch D, et al. (2005) Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. Contraception. 71(6):465-9.
Wildemeersch D, et al. (2016) Femilis 60 Levonorgestrel-Releasing Intrauterine System-A Review of 10 Years of Clinical Experience. Clin Med Insights Reprod Health. 10: 19-27.
Wildemeersch D, et al. (2017) Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS. Gynecol Endocrinol. 33(3):223-226.